UPDATED: Sanofi chief executive Viehbacher allegedly issues letter to company board defending his position
Chris Viehbacher, chief executive of French drug major Sanofi (Euronext: SAN), has urged the company’s board to clarify rumors that he is to be dismissed, according to a letter published in French business newspaper Les Echos, yesterday.
In the letter, Mr Viehbacher reportedly states that he has become aware of a ‘rumor’ that the president of the board is seeking a successor to his position, and asks that the board does not put the company ‘at risk’.
At Sanofi’s board meeting on Monday, Mr Viehbacher’s succession was not on the agenda, according to a press release sent out by the company. Reuters said it was not able to immediately authenticate the letter published by Les Echos.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze